



## GAVI Alliance Board Meeting

21-22 November 2013

Hotel Sofitel, Phnom Penh, Cambodia

Wednesday 20 November: Field Visits & Pre-Board meetings

Thursday 21 November: 08.30-18.15 (Board meeting Day One)

Friday 22 November: 09.00-17.30 (Board meeting Day Two)

Quorum: 14

### Declarations of interest

#### Declarations

Section 5.2 of the Conflict of Interest Policy states, "Annually, each member of the Board (including alternate Board members and Committee delegates)...shall complete and submit a conflict of interest form to be distributed by the Managing Director, Law and Governance." The following declarations were made by members of the Board on their most recent annual statements:

Member	Organisational Interests	Financial/Personal/Adviser Int
Dagfinn Høybråten, Chair	None	GAVI-appointed special adviser
Geeta Rao Gupta, Vice Chair	UNICEF	GAVI-appointed special adviser
Joan Awunyo-Akaba	Future Generations International (CSO constituency)	None
Wayne Berson	None	GAVI Fund Affiliate (Board)
Zulfiqar A. Bhutta	Aga Khan University (Research & Tech. Health Institutes)	None
Donal Brown	UK (UK/NOR/IRL)	TBD
Flavia Bustreo	WHO	None
Jenny Da Rin	AusAID (USA/AUS/JPN/KOR)	None
Awa Marie Coll-Seck	Government of Senegal	GAVI-appointed special adviser
H.R.H. the Infanta Cristina of Spain	None	"la Caixa" Foundation (Employee) Barcelona Inst. for Global Health (Board) GAVI-appointed special adviser
Suraya Dalil	Government of Afghanistan	GAVI-appointed special adviser
Mahima Datla	Dev. Ctry. Vaccine Manu. Net.	Biological E Limited (Employee)
Maria C. Freire	None	Johns Hopkins University (Family)
Ashutosh Garg	None	None
Gustavo Gonzalez-Canali	France (FRA/EC/LUX/GER)	None
A.F.M. Ruhul Haque	Government of Bangladesh	GAVI-appointed special adviser/TBD
Orin Levine	Bill & Melinda Gates Foundation	PATH (Family)
Yifei Li	None	None
Anders Nordström	Sweden (DEN/SWE/NED/NOR)	None

Member	Organisational Interests	Financial/Personal/Adviser Int
Christine J.D. Ondo	Government of Uganda	GAVI-appointed special adviser
Angela Santoni	Italy (ITA/ESP)	None
Richard Sezibera	None	GAVI-appointed special adviser
Andrei Usatii	Government of Moldova	GAVI-appointed special adviser
Johan Van Hoof	Int'l Fed. of Pharma. Manu. & Assoc.	Crucell/J&J (Employee)
George W. Welde, Jr	None	None
Seth Berkley (non-voting)	None	Gilead Sciences; Acumen Fund; Columbia, Brown and NY Univ.

Alternates who will potentially be present:

Member	Organisational Interests	Financial/Personal/Advisor Int
Nicholas Alipui	UNICEF	None
Saleh Banoita Tourab	Government of Djibouti	None
Robert Clay	USA (USA/AUS/JPN/KOR)	None
Armin Fidler	World Bank	None
Paul Richard Fife	NORAD (DEN/SWE/NED/NOR)	None
Juliman Fuad	Dev. Ctry. Vaccine Manu. Net.	BioPharma (Employee)
Micheline Gilbert	CIDA (CAN/IRL/UK)	None
Pe Thet Khin	Government of Myanmar	TBD
Dorothee Kinde Gazard	Government of Senegal	None
Steve Landry	Bill & Melinda Gates Foundation	None
Hussein Ali Mwinyi	Government of Tanzania	None
Jean-Marie Okwo-Bele	WHO	None
Olga Popova	Int'l Fed. of Pharma. Manu. & Assoc.	Crucell/J&J (Employee)
Walter Seidel	EC (FRA/EC/LUX/GER)	None
José Luis Solano	Spain (ITA/ESP)	None
Samba O. Sow	Center for Vaccine Development (Research & Tech. Health Institutes)	None
Naveen Thacker	(CSO constituency)	SERUM Institute (Rotavirus Data Safety Monitoring Board); GSK / SERUM and J&J (Indian Academy of Pediatrics Chair of two programmes)

Board members to be appointed who will potentially be present:

Member	Organisational Interests	Financial/Personal/Advisor Int
Tim Evans	World Bank	TBD
Ruhakana Rugunda	Government of Uganda	TBD
Walter Seidel	EC (FRA/EC/LUX/GER)	None

Alternate Board members to be appointed who will potentially be present:

Member	Organisational Interests	Financial/Personal/Advisor Int
Shanelle Hall	UNICEF	TBD
Emmanuel Lebrun-Damiens	EC (FRA/EC/LUX/GER)	TBD
Beate Stirø	Norway (DEN/SWE/NED/NOR)	TBD
Bheri Ramsaran	Government of Guyana	TBD

## Participation

Section 6.2 of the Policy states, “During the course of a Board or Board Committee meeting, a GAVI Person with an actual, perceived or potential Conflict of Interest shall disclose the interest to the Chair of the meeting as soon as possible upon learning of a possible Conflict of Interest and in no event later than at the beginning of discussion of the pertinent agenda item.”

Section 6.3 states, “It shall be the prerogative of the Chair of the meeting, in consultation with the Managing Director, Law and Governance, as appropriate, to determine the scope and level of a conflicted person’s participation in the discussion and the necessity of recusal from voting given the type of interest disclosed. The minutes of the meeting shall reflect the conflicted member’s disclosure and whether the conflicted member participated in the discussion and/or abstained from voting.”